Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | CDK4/6 inhibitor for hormone-positive breast cancer. | CDK4/6 inhibitor with QT effects, for hormone-positive breast cancer. |
| Body system | Cancer | Cancer |
| Drug class | CDK4/6 inhibitors | CDK4/6 inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription onlyWHO essential medicine |
| Main uses | Hormone-positive, HER2-negative advanced breast cancer | Hormone-positive, HER2-negative advanced breast cancer |
| How it works | Stops breast cancer cells from dividing. | Stops breast cancer cells from dividing. |
| Starts working | Depends on the cancer and regimen | Depends on the cancer and regimen |
| Half-life | About 29 hours | About 32 hours |
| Typical adult dose | Dosed by your cancer team according to the treatment protocol. | Dosed by your cancer team according to the treatment protocol. |
| Forms | Capsule, Tablet | Tablet |
| Common side effects | Low white cells, Tiredness, Nausea, Mouth sores, Hair thinning, Infections | Low white cells, Nausea, Tiredness, Diarrhoea, Hair thinning |
| Serious side effects | Febrile neutropenia, Lung inflammation, Blood clots | QT prolongation, Liver injury, Severe skin reactions |
| Don't take if | Pregnancy; Severe liver impairment | Long QT or uncontrolled heart rhythm disease; Pregnancy; Severe liver impairment |
| Alcohol | Best to limit. Alcohol can add to tiredness. | Best to limit. Alcohol can add to tiredness. |
| Pregnancy | Usually avoidedAvoid. | Usually avoidedAvoid. |
| Breastfeeding | Usually avoidedAvoid. | Usually avoidedAvoid. |
| In use since | — | — |
| Brand names | United States: IbranceUnited Kingdom: IbranceIndia: Ibrance, Palbociclib (generic) | United States: KisqaliUnited Kingdom: KisqaliIndia: Kisqali, Ribociclib (generic) |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H |
| ATC code | L01EF01 | L01EF02 |
Taken together
- ModeratePalbociclib + Ribociclib: Added bone marrow suppression
Both can lower white cells, red cells or platelets; together the risk of infection and bleeding rises.